European Union - English - EMA (European Medicines Agency)

ceft biopharma s.r.o. - ibritumomab tiuxetan - lymphoma, follicular - therapeutic radiopharmaceuticals - zevalin is indicated in adults.[90y]-radiolabelled zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. the benefit of zevalin following rituximab in combination with chemotherapy has not been established.[90y]-radiolabelled zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory cd20+ follicular b-cell non-hodgkin's lymphoma (nhl).

Israel - English - Ministry of Health

bayer israel ltd - ibritumomab tiuxetan 1.6 mg/ml - kit for radiopharmaceutical preparation infusion - ibritumomab tiuxetan(90y) - the 90y radiolabelled zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. the benefit of zevalin following rituximab in combination with chemotherapy has not been established.the 90y - radiolabelled zevalin is indicated for the treatment of adult patients with rituximab relapsed or refractory cd20+ follicular b-cell non-hodgkin's lymphama ( nhl).

Canada - English - Health Canada

auro pharma inc - ibritumomab tiuxetan - kit - 3.2mg - ibritumomab tiuxetan 3.2mg - radioactive agents